Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Hot anti-cancer medicines  > Keytruda CAS 1374853-91-4 Pembrolizumab

Keytruda CAS 1374853-91-4 Pembrolizumab 

Payment Terms: T/T,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: MOS-new 4
Production Capacity: 1kg/year
Delivery Date: 7 days
Name 1: Pembrolizumab
Means of Transport: Ocean,Land,Air
Packing: according to the customer's...
Name: Keytruda
CAS: 1374853-91-4

The first approved drug to block a cellular pathway known as pd-1


CAS: 1374853-91-4

As a humanized anti-pd1 monoclonal antibody, palmdrine (mk-3475, commodity name Keytruda, MSD) was approved by the food and drug administration (FDA) in September 2014 for the treatment of advanced or unresectable malignant melanoma as an immune checkpoint inhibitor (ICB). However, it has been found that pd-1 inhibitors can produce the side effects of autoimmune injury to the human body's multiple systems, such as hepatitis, pneumonia and myocardial injury.

Adaptation disease

1) unresectable or metastatic melanoma and plymma after disease progression and, such as BRAF V600 positive mutation.
2) fda-approved tests identified metastatic NSCLC and disease progression after chemotherapy with or with platinum-based chemotherapy. Patients treated with KEYTRUDA before fda-approved therapy had EGFR or ALK genomic tumor distortion in these patients.

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: